Enhanced overall and progression-free survival in advanced melanoma patients undergoing targeted therapy alongside antithrombotic treatment - Insights from a multicenter study involving 1296 patients from the prospective skin cancer registry ADOReg - Articles - Dermatology · Immunology · Rheumatology

Melanoma and Skin Cancer

Determinants of adjuvant treatment choice between immunotherapy (immune checkpoint inhibitor) and targeted therapy in resected stage III BRAF V600-mutated cutaneous melanoma: a multicenter observational study: MELADJ3

Melanoma Res

Devoldere A, Bouche O, Barbe C, Didier K, Colbach S, Brocard FG, Carlier C

doi: 10.1097/CMR.0000000000001083

Rheumatoid Arthritis

Prospective study on mental status in rheumatoid arthritis patients on tumour necrosis factor vs non- tumour necrosis factor-targeted therapies after achieving treatment target

Rheumatology (Oxford)

Fujii T, Murata K, Nakabo S, Onishi A, Murakami K, Tanaka M, Morinobu A, Matsuda S

doi: 10.1093/rheumatology/keaf598

Melanoma and Skin Cancer

Tumor necrosis alpha inhibitor therapy is associated with increased long-term risk of non-melanoma skin cancer and melanoma: a retrospective cohort study

J Am Acad Dermatol

Driscoll CB, Schwab G, Quan VL, McKenney J, Hooper MJ, Shankar Ramesh Kumar SK, Kundu RV, Kundu SD

doi: 10.1016/j.jaad.2026.02.035

Melanoma and Skin Cancer

Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy

J Eur Acad Dermatol Venereol

Schumann K, Klespe KC, Mauch C, Loquai C, Schultheis U, Börger S, Thiem A, Emmert S, Hoellwerth M, Koelbinger P, Nguyen VA, Wanner M, Richtig E, Peitsch WK, Harth W, Zenderowski V, Braun AD, Mengoni M, Dummer R, Mangana J, Maul LV, Meis F, Rappersberger K, Persa OD, Biedermann T, Posch C

doi: 10.1111/jdv.20708

Psoriatic Arthritis

Real-world evidence on palmoplantar pustulosis: Patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study

Br J Dermatol

Graier T, Bordag N, Weger W, Laschober N, Ratzinger G, Jonak C, Prillinger K, Müllegger R, Mlynek A, Lange-Asschenfeldt B, Häring N, Hoetzenecker W, Posch C, Ellersdorfer C, Sator P, Gruber B, Hofer A, Gruber-Wackernagel A, Legat FJ, Großschädl K, Gruber V, Schadelbauer E, Repelnig M, Gressenberger P, Widnig A, Falkensteiner K, Salmhofer W, Wolf P

doi: 10.1093/bjd/ljaf394

Melanoma and Skin Cancer

A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England 2016-21

Br J Dermatol

Mistry K, Jeffrey P, Levell NJ, Kennedy O, Richardson K, Craig P, Bright C, Taylor S, Ragan J, Karponis D, Pethick J, Lavelle K, McRonald F, Hardy S, Vernon S, Lorigan P, Venables ZC

doi: 10.1093/bjd/ljaf351

Acne

Safe and Effective Acne Treatment Across Skin Types with a 1726 nm Sebum-Selective Laser: One Year Data from a Prospective Multicenter Study

J Am Acad Dermatol

Goldberg D, Ronan S, Bhatia A, Dhawan SS, Green JB, Kilmer SL, Kwan W, Stein Gold L, Weiss JS, Doucette M, Karavitis M, Dover JS

doi: 10.1016/j.jaad.2025.09.077

Melanoma and Skin Cancer

Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patients

Ann Dermatol Venereol

David C, Coquelle C, Le Corre Y, L'Orphelin JM, Nardin C, Aubin F, Cassecuel J, Dreno B, Wierzbiecka-Hainault E, Bens G, Beneton N, Dinulescu M, Kervarrec T, Saiag P, Blom A, Samimi M

doi: 10.1016/j.annder.2025.103411

Systemic Lupus Erythematosus

Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years

Arthritis Res Ther

Kojima K, Ichinose K, Umeda M, Shimizu T, Sato S, Suzuki T, Nakashima Y, Okada A, Horai Y, Fujikawa K, Aramaki T, Miyashita T, Furuyama M, Matsuoka N, Kawakami A

doi: 10.1186/s13075-025-03581-0

Related content

Determinants of adjuvant treatment choice between immunotherapy (immune checkpoint inhibitor) and targeted therapy in resected stage III BRAF V600-mutated cutaneous melanoma: a multicenter observational study: MELADJ3

Prospective study on mental status in rheumatoid arthritis patients on tumour necrosis factor vs non- tumour necrosis factor-targeted therapies after achieving treatment target

Tumor necrosis alpha inhibitor therapy is associated with increased long-term risk of non-melanoma skin cancer and melanoma: a retrospective cohort study

Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy

Real-world evidence on palmoplantar pustulosis: Patient characteristics, diagnostic challenges and predictive factors for treatment survival - a retrospective registry study

A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England 2016-21

Safe and Effective Acne Treatment Across Skin Types with a 1726 nm Sebum-Selective Laser: One Year Data from a Prospective Multicenter Study

Survival outcomes and response to immune checkpoint inhibitors among patients with advanced Merkel cell carcinoma: a retrospective study of 81 patients

Enhancing systemic lupus erythematosus treatment outcomes with an early initiation of belimumab: insights from a multicenter retrospective study within the first five years